Vimpat®-Zusatzbehandlung bei therapieresistenter EpilepsieArnold · Clinical Epileptology2010PDF150 KB
The anti-epileptic drug lacosamide (Vimpat®) has anxiolytic property in rodentsHiggins · European Journal of Pharmacology2009PDF446 KB
Synthesis of Lacosamide (Vimpat) and Its Derivatives from Aziridine-(2R)-carboxylateJeong · Synthesis2016PDF237 KB
Lacosamid (Vimpat®): Bericht eines Expertentreffens zu einem neuen Medikament zur Zusatzbehandlung fokaler AnfälleSchmidt · Zeitschrift für Epileptologie2008PDF358 KB
The EMA's CHMP Recommends the Permanent Discontinuation of Lacosamide [Vimpat] 15 mg/mL Syrup.Adis International Limited (now part of Wolters Kluwer Health)2011PDF120 KB
The EMA Is Recommending the Authorisation of Lacosamide [Vimpat] Syrup for Patients with EpilepsyAdis International Limited (now part of Wolters Kluwer Health)2012PDF133 KB
First asymmetric synthesis of the antiepileptic drug Lacosamide (Vimpat®) based on a hydrolytic kinetic resolution strategyMuthukrishnan · Tetrahedron Asymmetry2011PDF425 KB